Sign in
CompletedPhase 2

A trial to compare efficacy and safety of follitropin delta versus placebo (inactive treatment) in the treatment of men with idiopathic infertility (unexplained reduction of semen quality).

Key facts

Who runs it
Ferring Pharmaceuticals A/S
Where
Belgium, Denmark, Germany, Italy, Spain, and Sweden10 sites in 6 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
197 people enrolled
Started
12 Jan 2023
Ended
23 Oct 2024
Type of study
Interventional
Record updated
16 October 2024

Who can take part

Age
18 years to 64 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • History of infertility for 12-60 months with current partner at randomisation
  • Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health
  • Current partner fulfilling the criteria below: a) Pre-menopausal woman between the ages of 18 and 35 years. b) Regular menstrual cycles of 21-35 days. c) No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation. d) Agree not to obtain infertility treatment outside of this trial for 9 months from randomisation of male subject
  • Men between the ages of 18 and 50 years
  • Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
  • Total sperm motility of ≥10% at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
  • Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
  • Serum follicle-stimulating hormone (FSH) levels of 1.5-8.0 IU/L (measured at central laboratory) at screening
  • Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening
  • Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening
  • Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomisation

Who cannot take part

  • Previous FSH treatment not leading to conception
  • Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening
  • Past or current use of finasteride within 3 months prior to screening
  • Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • Any history of anatomical disorder of the pituitary gland or testes
  • Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact fertility
  • Known history of cryptorchidism, testicular torsion, or orchitis
  • Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes
  • Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening
  • Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable)
  • Known abnormal karyotype (including Y-chromosome microdeletion)

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the effect of FE 999049 treatment of men with idiopathic infertility on the chance of spontaneous pregnancy in their female partners.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility
Record updated
16 October 2024